Use of mycophenolate mofetil for the treatment of fibrotic hypersensitivity pneumonitis

The optimal treatment of fibrosing hypersensitivity pneumonitis (fHP) is not well understood. The aim of the study was to obtain information about the usefulness of mycophenolate mofetil (MMF) in its treatment. Quasi-experimental analysis of patients diagnosed with fHP and treated with MMF for one y...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of the medical sciences 2025-01, Vol.369 (1), p.24-34
Main Authors: Casal, Ana, Suárez-Antelo, Juan, Gude, Francisco, Lado-Baleato, Óscar, Otero, Borja, Toubes, María E., Ferreiro, Lucía, Rodríguez-Núñez, Nuria, Valdés, Luis
Format: Article
Language:English
Subjects:
Fibrotic hypersensitivity pneumonitis
Interstitial lung disease
Mycophenolate mofetil
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal treatment of fibrosing hypersensitivity pneumonitis (fHP) is not well understood. The aim of the study was to obtain information about the usefulness of mycophenolate mofetil (MMF) in its treatment. Quasi-experimental analysis of patients diagnosed with fHP and treated with MMF for one year, in a single centre. From the start of treatment, data collection was prospective. 73 were included and 58 completed the study. FVC% and DLCO% decreased until starting MMF (year -1 to year 0). After completion of treatment (year 1), FVC% stabilised (p=0.336) and DLCO% improved significantly (p=0.004) compared to year 0. Dyspnoea, number of patients without corticosteroids and mean corticosteroid dose also improved significantly (p
ISSN:0002-9629
1538-2990
1538-2990
DOI:10.1016/j.amjms.2024.07.021